BioSpace News Archive

Novo Nordisk specializes in the diabetes market. The company appears to be making an entry into the Alzheimer’s market, which isn’t as unusual or unexpected as it initially sounds.

The positions will be in manufacturing, assembly and packaging. The NC Department of Commerce approved the incentives this morning.

Sensyne Health plc, the British Clinical AI technology company, announces its Interim Results for the 6 months ended 31 October 2019.

Retrospective Clinical Study Uses Highly Multiplexed Imaging Mass Cytometry to Reveal Previously Unknown Features of the Tumor Microenvironment and Novel Breast Cancer Subgroups

Pharming Group N.V. announced it has received European Medicines Agency approval of a Type II Variation for a new production facility for the Company’s lead product, RUCONEST®.

Voluntary public share buyback offer against cash payment in a purchase price range of EUR 1.60 to EUR 1.85 per share

Exosomics SpA, the leading extracellular vesicles biotech company, announced that it has implemented NanoFCM Co., Ltd’s NanoAnalyzer instrument to offer sophisticated contract research and measurement services worldwide.

EmphyCorp Inc. www.EmphyCorp.com, a Private Corporation, was proud to announce on January 14th, 2020 the use of its globally patented non-steroidal nasal spray technology for the treatment of all Lung Diseases, with clinical data to support the use of our N115 Nasal Spray for delivery of antivirals, antimicrobials, insulin, and a host of other drugs to treat other diseases.

Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes.

Organicell Regenerative Medicine Inc. (OTCPK:BPSR) (the “Company”) is pleased to provide shareholders and the investment community with an update on operations since its filing on November 1, 2018 of the Company’s Annual Report on Form filing of Form 10-K for the year ended October 31, 2017, as well as the status of becoming fully compliant with SEC reporting obligations.